Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 3 trial
J Am Acad Dermatol
.
2024 Nov;91(5):984-986.
doi: 10.1016/j.jaad.2024.07.1447.
Epub 2024 Jul 20.
Authors
Yan Zhao
1
,
Litao Zhang
2
,
Jianzhong Zhang
3
;
CM310AD005 Study Investigators
Affiliations
1
Department of Dermatology, Peking University People's Hospital, Beijing, China.
2
Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China.
3
Department of Dermatology, Peking University People's Hospital, Beijing, China. Electronic address: rmzjz@126.com.
PMID:
39038559
DOI:
10.1016/j.jaad.2024.07.1447
No abstract available
Keywords:
IL-4Rα; double-blind; efficacy; moderate-to-severe atopic dermatitis; safety; stapokibart.